Molecular responses in e19a2 BCR-ABL1 chronic myeloid leukemia

Publication date: Available online 12 March 2020Source: Leukemia Research ReportsAuthor(s): Laura Kearney, Mireille Crampe, Eibhlin Conneally, Janusz Krawczyk, Senthil Kumar, Philip T. Murphy, Vitaliy Mykytiv, Mary-Frances Ryan, Stephen E. Langabeer
Source: Leukemia Research Reports - Category: Hematology Source Type: research

Related Links:

Publication date: June 2020Source: Clinical Lymphoma Myeloma and Leukemia, Volume 20, Issue 6Author(s): Olga V. Lazareva, Anna G. Turkina, Ekatarina Yu. Chelysheva, Anton A. Kulikovsky, Maria V. Galayko, Olga M. Senderova, Valentina M. Pepeliaeva, Sergey V. Meresiy, Alexandr S. Luchinin, Galina I. Milutina, Lyubov V. Gavrilova, Lyudmila B. Avdeeva, Elena B. Dasheeva, Olga Yu. Vinogradova, Hunan L. Julhakyan, Sergey M. Kulikov
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion: Moderate anemia is a common concomitant symptom in CML-CP patients and is associated with high-risk CML, but its occurrence does not affect the survival of CML-CP patients in TKI era. PMID: 32432512 [PubMed - in process]
Source: Hematology - Category: Hematology Tags: Hematology Source Type: research
Tyrosine kinase inhibitors represent the standard of care for several diseases and drug targets in hematologic malignancies. Infectious complications vary by disease status and prior therapy, but overall incidence of infections generally is low. In chronic diseases, such as chronic myeloid leukemia and chronic lymphocytic leukemia, patients can remain on tyrosine kinase inhibitor therapy for many years, with few infectious complications from therapy. Bruton tyrosine kinase inhibitors overall are well tolerated in lymphoproliferative disorders, with long-term follow-up of many years in patients with chronic lymphocytic leuk...
Source: Infectious Diseases Clinics of North America - Category: Infectious Diseases Authors: Source Type: research
Chronic myeloid leukemia (CML) pathogenesis is mainly driven by the oncogenic breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1 (BCR-ABL) fusion protein. Since BCR-ABL displays abnorma...
Source: Clinical Epigenetics - Category: Research Authors: Tags: Research Source Type: research
.
Source: Nutrition and Cancer - Category: Cancer & Oncology Authors: Source Type: research
lçın AS Abstract Flavonoids are phenolic substances with chemo-preventive and chemotherapeutic properties. They are widely found in fruits and vegetables. The polyphenols quercetin and curcumin have antioxidant, anti-inflammatory, anti-carcinogenic, and pro-apoptotic properties. They were successfully used against different human cancers, especially chronic myeloid leukemia cancer cells. We have previously investigated anti-proliferative and apoptotic effects of quercetin and curcumin combination in K562 cells. Our data showed that they had beneficial synergistic effects. Based on these findings, we aimed ...
Source: Nutrition and Cancer - Category: Cancer & Oncology Authors: Tags: Nutr Cancer Source Type: research
We read the study of Schmidt et al. [1] with great interest, in which they retrospectively analyzed 215 patients with chronic myeloid leukemia (CML) who relapsed after allogeneic hematopoietic stem cell transplantation (alloHSCT). The patients were divided into three groups according to the treatment applied following posttransplant relapse; as patients receiving tyrosine kinase inhibitor (TKI) alone, cases with TKI  + donor lymphocyte infusion (DLI) combination arm, and DLI alone.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Circular RNAs (circRNAs), which act as initiators and promoters of various diseases, were thought to be mostly noncoding RNAs (ncRNAs) in eukaryotes, until recent studies confirmed that some circRNAs have the function of encoding proteins. Accumulating research findings have proved that dysregulation of circRNAs is associated with the developmental process of multiple cancers. circHIPK3, an example of circRNA, is frequently expressed in many diseases, such as diabetes, age-related cataract, idiopathic pulmonary fibrosis, preeclampsia, osteoblasts, and retinal vascular dysfunction, leading to disease development and progres...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
The objective is to evaluate the long-term efficacy and the occurrence of vascular occlusion with second-generation BCR-ABL TKIs compared with imatinib in patients with CML. Three scientific databases, a clinical registry and abstracts from congress were searched to identify all randomized controlled trials that compared a second-generation BCR-ABL TKI to imatinib in patients with CML. Outcomes extracted were overall survival, major molecular response and complete cytogenetic response, arterial occlusive events and venous thromboembolism. These data were synthesized by odds ratios using a fixed-effect model. This meta-anal...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
In this study, we treated human hematopoietic stem and progenitor cells (HSPCs) harvested from a patient with chronic myelogenous leukemia (CML) with gemcitabine/carboplatin. Thereafter, scRNA-seq was performed to distinguish transcriptional effects induced by gemcitabine/carboplatin. Gene expression was calculated and evaluated among cells within and between samples compared to untreated cells. Cell cycle analysis showed that the treatments effectively decrease cell proliferation, indicated by the proportion of cells in the G2M-phase dropping from 35% in untreated cells to 14.3% in treated cells. Clustering and t-SNE show...
Source: Genes - Category: Genetics & Stem Cells Authors: Tags: Article Source Type: research
More News: Chronic Leukemia | Chronic Myeloid Leukaemia | Hematology | Leukemia